News

News

Yuhan Corporation signs an MOU with Imperial College London

Yuhan Corporation has signed a memorandum of understanding for strategic alliance with Imperial College London to participate in the “ICiC (Imperial Confidence in Concept)” program and fund their proof of ...
Read More

Yuhan announced a neurodegenerative disease Research & BD alliance with a leading university and biotech company in Korea

Yuhan Corporation has signed a three-party agreement with Sungkyunkwan University (SKKU) and Imnewrun Biosciences to build a Brain Disease R&BD ecosystem. For the first time in Korea, a pharmaceutical company, ...
Read More

Yuhan to license out a gastrointestinal drug candidate to Processa for $415 million

Yuhan Corporation entered into a licensing agreement worth up to $415 million with Processa Pharmaceuticals for the development of YH12852, a small molecule drug in development for the treatment of ...
Read More

[Job Opening] Business Development Manager – San Diego office

Yuhan USA Corporation was established in January 2018 as a wholly-owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 94-year heritage. As an outpost of Yuhan’s globalization strategy, ...
Read More

Yuhan-AbClon now in the race for a COVID-19 therapeutic antibody

Yuhan and AbClon have joined the list of pharmaceutical companies that are in the race to develop a therapeutic antibody for COVID-19. They have identified a multifariously adaptive candidate for ...
Read More

Yuhan expands its allergy treatment pipeline with the in-license of GI-301 from GI Innovation

Yuhan Corporation has in-licensed GI Innovation's allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion. Yuhan and GI Innovation’s collaboration to develop next-generation ...
Read More

Yuhan Corporation to recoup KRW 200 billion investment in five years

Yuhan Corporation's global R&D and open innovation strategy - in which they introduce early assets from the startups, conduct preclinical & early clinical studies, then license them out to the ...
Read More

J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation

Here’s an update from our business partner Janssen Biotech that JNJ-6372 in combination with Lazertinib (YH25448), a novel third-generation EGFR TKI for advanced NSCLC that Yuhan Corporation out-licensed to them ...
Read More

Yuhan to invest 14% of its sales in R&D this year for “Lazertinib’s Phase-3 trial & Global Open Innovation

In 2020, Yuhan Corporation is going to invest the largest amount in history for its R&D program to speed up the development of Lazertinib (YH25448) – the first-line treatment for ...
Read More

Yuhan USA’s 2019 Recap

With 2020 just around the corner, let's take a look back at our 2019! It has been a wonderful year for us here at Yuhan USA and may the next ...
Read More